Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin Lymphoma

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1, 2012, Pages 76-83

  Cote, Gregory M ^a   Hochberg, Ephraim P ^a   Muzikansky, Alona ^a   Hochberg, Fred H ^a   Drappatz, Jan ^b   McAfee, Steven L ^a   Batchelor, Tracy T ^a   LaCasce, Ann S ^b   Fisher, David C ^b   Abramson, Jeremy S ^a   Armand, Philippe ^b   Chen, Yi Bin ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Autologous stem cell transplantation; CNS lymphoma; Lymphoma; PCNSL; Thiotepa

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETIRACETAM; ETOPOSIDE; FAMCICLOVIR; FLUCONAZOLE; FUROSEMIDE; LISINOPRIL; MESNA; METHOTREXATE; METOPROLOL; PHENYTOIN; PREDNISONE; QUINOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; STEROID; TEMOZOLOMIDE; THIOTEPA; URSODEOXYCHOLIC ACID; VINCRISTINE;

ADULT; AGED; ARTICLE; ATAXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BK VIRUS; BRAIN RADIOGRAPHY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYSTITIS; DISEASE SEVERITY; DRUG FATALITY; DRUG MEGADOSE; DYSPHAGIA; EMPYEMA; ENGRAFTMENT SYNDROME; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; LUNG ABSCESS; LUNG TOXICITY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PNEUMONIA; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM NON HODGKIN LYMPHOMA; PRIMARY CENTRAL NERVOUS SYSTEM NONHODGKIN LYMPHOMA; PROGRESSION FREE SURVIVAL; PULMONARY CANDIDIASIS; SEIZURE; SKIN CANDIDIASIS; TOTAL PARENTERAL NUTRITION; TREATMENT RESPONSE; VEIN OCCLUSION; VENO OCCLUSI;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855417603     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.006     Document Type: Article

References (27)

1. Abrey L.E., DeAngelis L.M., Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998, 16:859-863.
2. Batchelor T., Carson K., O'Neill A., et al. Treatment of primaryCNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003, 21:1044-1049.
3. DeAngelis L.M., Seiferheld W., Schold S.C., Fisher B., Schultz C.J. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002, 20:4643-4648.
4. Gerstner E.R., Carson K.A., Grossman S.A., Batchelor T.T. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 2008, 70:401-402.
5. Poortmans P.M., Kluin-Nelemans H.C., Haaxma-Reiche H., et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 2003, 21:4483-4488.
6. Harder H., Holtel H., Bromberg J.E., et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004, 62:544-547.
7. Boehme V., Schmitz N., Zeynalova S., Loeffler M., Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009, 113:3896-3902.
8. Boehme V., Zeynalova S., Kloess M., et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007, 18:149-157.
9. van Besien K., Ha C.S., Murphy S., et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998, 91:1178-1184.
10. Cheng T., Forsyth P., Chaudhry A., et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003, 31:679-685.
11. Alvarnas J.C., Negrin R.S., Horning S.J., et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000, 6:352-358.
12. van Besien K., Przepiorka D., Mehra R., et al. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol 1996, 14:3036-3042.
13. Williams C.D., Pearce R., Taghipour G., Green E.S., Philip T., Goldstone A.H. Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome-a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 1994, 12:2415-2422.
14. Abrey L.E., Moskowitz C.H., Mason W.P., et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. JClin Oncol 2003, 21:4151-4156.
15. Colombat P., Lemevel A., Bertrand P., et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006, 38:417-420.
16. Illerhaus G., Marks R., Ihorst G., et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006, 24:3865-3870.
17. Illerhaus G., Marks R., Muller F., et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 2009, 20:319-325.
18. Illerhaus G., Muller F., Feuerhake F., Schafer A.O., Ostertag C., Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008, 93:147-148.
19. Soussain C., Hoang-Xuan K., Taillandier L., et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008, 26:2512-2518.
20. Soussain C., Suzan F., Hoang-Xuan K., et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001, 19:742-749.
21. Montemurro M., Kiefer T., Schuler F., et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007, 18:665-671.
22. Egorin M.J., Akman S.R., Gutierrez P.L. Plasma pharmacokinetics and tissue distribution of thiotepa in mice. Cancer Treat Rep 1984, 68:1265-1268.
23. Heideman R.L., Cole D.E., Balis F., et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989, 49:736-741.
24. Vassal G., Gouyette A., Hartmann O., Pico J.L., Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989, 24:386-390.
25. Hassan M., Oberg G., Ericson K., et al. Invivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 1992, 30:81-85.
26. Hassan M., Ehrsson H., Smedmyr B., et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 1989, 4:113-114.
27. Wiebe V.J., Smith B.R., DeGregorio M.W., Rappeport J.M. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992, 13:241-270.